BBIO BridgeBio Pharma Inc

Price (delayed)

$66.44

Market cap

$8.14B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.41

Enterprise value

$8.26B

Sector: Healthcare
Industry: Biotechnology

Highlights

BridgeBio Pharma's gross margin has increased by 10% YoY and by 7% from the previous quarter
BridgeBio Pharma's quick ratio has decreased by 29% YoY but it has increased by 4.5% from the previous quarter
BBIO's net income has dropped by 78% year-on-year and by 16% since the previous quarter
BBIO's equity has dropped by 64% year-on-year and by 38% since the previous quarter

Key stats

What are the main financial stats of BBIO
Market
Shares outstanding
122.57M
Market cap
$8.14B
Enterprise value
$8.26B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
49.65
Price to sales (P/S)
357.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
376.39
Earnings
Revenue
$21.95M
EBIT
-$373.47M
EBITDA
-$374.09M
Free cash flow
-$386.63M
Per share
EPS
-$3.41
Free cash flow per share
-$3.27
Book value per share
$1.34
Revenue per share
$0.19
TBVPS
$6.67
Balance sheet
Total assets
$787.69M
Total liabilities
$569.31M
Debt
$483.75M
Equity
$163.76M
Working capital
$669.68M
Liquidity
Debt to equity
2.95
Current ratio
9.85
Quick ratio
9.49
Net debt/EBITDA
-0.31
Margins
EBITDA margin
-1,704.6%
Gross margin
100%
Net margin
-1,832.7%
Operating margin
-1,939.4%
Efficiency
Return on assets
-48.5%
Return on equity
-132%
Return on invested capital
-59.3%
Return on capital employed
-52.5%
Return on sales
-1,701.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BBIO stock price

How has the BridgeBio Pharma stock price performed over time
Intraday
-1.88%
1 week
-4.72%
1 month
1.05%
1 year
106.14%
YTD
-6.57%
QTD
-6.57%

Financial performance

How have BridgeBio Pharma's revenue and profit performed over time
Revenue
$21.95M
Gross profit
$21.95M
Operating income
-$425.63M
Net income
-$402.2M
Gross margin
100%
Net margin
-1,832.7%
BBIO's operating margin has shrunk by 118% QoQ and by 105% YoY
BBIO's net margin has dropped by 117% year-on-year and by 115% since the previous quarter
BBIO's net income has dropped by 78% year-on-year and by 16% since the previous quarter
BBIO's operating income has dropped by 68% year-on-year and by 18% since the previous quarter

Growth

What is BridgeBio Pharma's growth rate over time

Valuation

What is BridgeBio Pharma stock price valuation
P/E
N/A
P/B
49.65
P/S
357.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
376.39
BBIO's EPS is down by 42% year-on-year and by 16% since the previous quarter
BBIO's equity has dropped by 64% year-on-year and by 38% since the previous quarter
BridgeBio Pharma's revenue has decreased by 46% from the previous quarter and by 18% YoY

Efficiency

How efficient is BridgeBio Pharma business performance
BBIO's ROS has dropped by 111% since the previous quarter and by 108% year-on-year
The ROIC has soared by 71% YoY and by 11% from the previous quarter
The return on equity has surged by 69% year-on-year but it has declined by 44% since the previous quarter
The ROA has contracted by 11% from the previous quarter

Dividends

What is BBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BBIO.

Financial health

How did BridgeBio Pharma financials performed over time
BBIO's total assets is 38% greater than its total liabilities
The current ratio has decreased by 30% YoY but it has increased by 6% QoQ
BridgeBio Pharma's quick ratio has decreased by 29% YoY but it has increased by 4.5% from the previous quarter
BBIO's debt is 195% greater than its equity
BBIO's equity has dropped by 64% year-on-year and by 38% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.